NGL FINECHEM
|
The Current P/E Ratio of NGL FINECHEM is 54.65.
| Share Price | ₹1,823.6 | Feb 03,2026 |
| Market Cap | ₹1,130.6 Cr | |
| Earnings-TTM | ₹20.7 Cr | TTM-Consolidated Results |
| Price/Earnings | 54.65x | Calculated as Market Cap/Earnings |
|---|---|---|
| Explore Stock Analytics | ||
Definition & Calculation of PE (Price/Earnings) ratio of NGL FINECHEM
P/E =
Market Capitalization
/ Net Income
or, using per-share numbers:
P/E = Stock Price /
Earnings Per Share (EPS)
Current Market Cap [ ₹1,130.6 Cr] as on Feb 03,2026
(/) Earnings [ ₹20.7 Cr] based on TTM-Consolidated Results
(=) P/E Ratio [ 54.65x ]
Thus, for NGL FINECHEM , the investors are currently willing to pay 54.65 times earnings to own 1 share of the company.
PE Multiples are the most widely used valuation multiple in practice.
Since P/E ratio uses Net Income in the calculation, P/E multiples are not always reliable for valuing companies with negative earnings.
In such cases, you may consider using Price to Book ratio or Price to Sales ratio of NGL FINECHEM !
P/E ratios, also, would not adjust for differences in the capital structure between companies.
The chart below summarizes the trend in P/E Ratio of NGL FINECHEM over the last five years.
Historical PE (Price/Earnings) ratio chart of NGL FINECHEM
PE Ratio Performance Analysis for NGL FINECHEM
- NGL FINECHEM 's p/e ratio for fiscal years ending Mar2025 to Mar2021 averaged 28.31x.
- NGL FINECHEM 's operated at median p/e ratio of 31.37x from fiscal years ending March 2018 to 2022.
- Looking back at the last 5 fiscal years, NGL FINECHEM 's p/e ratio peaked in Mar2023 at 36.22x.
- NGL FINECHEM 's p/e ratio hit its five-year low in Mar2021 of 16.74x.
How does NGL FINECHEM 's P/E Ratio benchmark against top 10 peers in Pharmaceuticals & Drugs Industry?
| Peer Comparison (Pharmaceuticals & Drugs Industry) | Earnings-TTM (Cr) | PE Ratio | Market Cap |
|---|---|---|---|
| NGL FINECHEM | 20.69 | 54.65 | 1,130.6 |
| SUN PHARMACEUTICAL INDUSTRIES LTD | 11,001.40 | 37.14 | 408,559.0 |
| DIVIS LABORATORIES LTD | 2,485.00 | 66.33 | 164,827.0 |
| CIPLA LTD | 4,544.70 | 23.51 | 106,825.0 |
| TORRENT PHARMACEUTICALS LTD | 2,140.00 | 63.99 | 136,942.0 |
| DR REDDYS LABORATORIES LTD | 5,508.70 | 18.71 | 103,077.0 |
| MANKIND PHARMA LTD | 1,796.65 | 49.53 | 88,996.6 |
| ZYDUS LIFESCIENCES LTD | 4,973.40 | 18.27 | 90,857.9 |
| LUPIN LTD | 4,347.53 | 22.98 | 99,911.5 |
| AUROBINDO PHARMA LTD | 3,447.75 | 20.66 | 71,215.0 |
| ABBOTT INDIA LTD | 1,508.95 | 37.84 | 57,096.1 |
Pharmaceuticals & Drugs Industry Benchmark (Top 10) PE Analysis vs NGL FINECHEM 's P/E Ratio
| Top 10 Industry Peers | PE Ratio |
|---|---|
| Min industry PE | 18.27x |
| Max industry PE | 66.33x |
| Median industry PE | 37.14x |
| Average industry PE | 37.60x |
You may also like the below Video Courses